Detection/NN
of/IN
the/DT
chromosome/NN
16/CD
CBF/NN
beta-MYH11/NN
fusion/NN
transcript/NN
in/IN
myelomonocytic/JJ
leukemias/NNS
./.

Karyotypic/JJ
detection/NN
of/IN
chromosomal/JJ
16/CD
abnormalities/NNS
classically/RB
associated/VBN
with/IN
AML/NN
M4Eo/NN
can/MD
be/VB
difficult/JJ
./.
=====
Characterization/NN
of/IN
the/DT
two/CD
genes/NNS
involved/VBN
in/IN
the/DT
inv(16)(p13q22)/NN
,/,
CBF/NN
beta/NN
and/CC
MYH11/NN
,/,
has/VBZ
allowed/VBN
the/DT
detection/NN
of/IN
fusion/NN
transcripts/NNS
by/IN
reverse-transcriptase/NN
polymerase/NN
chain/NN
reaction/NN
(/(
RT-PCR/NN
)/)
./.
=====
We/PRP
have/VBP
analyzed/VBN
CBF/NN
beta-MYH11/NN
fusion/NN
transcripts/NNS
by/IN
RT-PCR/NN
in/IN
myelomonocytic/JJ
leukemias/NNS
,/,
with/IN
or/CC
without/IN
eosinophilia/NN
,/,
to/TO
determine/VB
whether/IN
their/PRP$
presence/NN
correlates/VBZ
with/IN
morphology/NN
./.
=====
Fifty-three/CD
cases/NNS
(/(
11/CD
AML/NN
M4Eo/NN
;/:
1/CD
AML/NN
M4/NN
with/IN
atypical/JJ
abnormal/JJ
eosinophils/NNS
(/(
AML/NN
M4/NN
"/``
Eo/NN
"/''
)/)
;/:
29/CD
AML/NN
M4/NN
;/:
8/CD
AML/NN
M5/NN
;/:
3/CD
CMML/NN
;/:
and/CC
1/CD
AML/NN
M2/NN
with/IN
eosinophilia/NN
)/)
were/VBD
analyzed/VBN
./.
=====
All/DT
11/CD
typical/JJ
AML/NN
M4Eo/NN
were/VBD
CBF/NN
beta-MYH11/NN
positive/JJ
./.
=====
The/DT
single/JJ
case/NN
of/IN
AML/NN
M4/NN
with/IN
distinctive/JJ
eosinophil/NN
abnormalities/NNS
was/VBD
negative/JJ
by/IN
karyotype/NN
,/,
RT-PCR/NN
and/CC
fluorescent/JJ
in/FW
situ/FW
hybridization/NN
(/(
FISH/NN
)/)
./.
=====
Three/CD
of/IN
29/CD
(/(
10/CD
%/NN
)/)
AML/NN
M4/NN
without/IN
abnormal/JJ
eosinophils/NNS
were/VBD
CBF/NN
beta-MYH11/NN
positive/JJ
,/,
1/CD
of/IN
which/WDT
did/VBD
not/RB
show/VB
any/DT
apparent/JJ
chromosome/NN
16/CD
abnormalities/NNS
by/IN
classical/JJ
metaphase/NN
analysis/NN
(/(
2/CD
not/RB
tested/VBN
)/)
./.
=====
Both/DT
cases/NNS
tested/VBN
also/RB
showed/VBD
MYH11/NN
genomic/JJ
rearrangement/NN
./.
=====
None/NN
of/IN
the/DT
other/JJ
leukemias/NNS
were/VBD
RT-PCR/NN
positive/JJ
./.
=====
Follow-up/NN
of/IN
three/CD
patient/NN
showed/VBD
residual/JJ
positivity/NN
in/IN
apparent/JJ
complete/JJ
remission/NN
./.
=====
These/DT
data/NNS
show/VBP
that/IN
CBF/NN
beta-MYH11/NN
fusion/NN
transcripts/NNS
occur/VBP
not/RB
only/RB
in/IN
the/DT
vast/JJ
majority/NN
of/IN
typical/JJ
AML/NN
M4Eo/NN
,/,
but/CC
also/RB
in/IN
approximately/RB
10/CD
%/NN
of/IN
AML/NN
M4/NN
without/IN
eosinophilic/JJ
abnormalities/NNS
,/,
a/DT
much/RB
higher/JJR
incidence/NN
than/IN
the/DT
sporadic/JJ
reports/NNS
of/IN
chromosome/NN
16/CD
abnormalities/NNS
in/IN
AML/NN
M4/NN
would/MD
suggest/VB
./.
=====
Taken/VBN
together/RB
with/IN
the/DT
detection/NN
of/IN
CBF/NN
beta-MYH11transcripts/NNS
in/IN
the/DT
absence/NN
of/IN
apparent/JJ
chromosome/NN
16/CD
abnormalities/NNS
by/IN
classical/JJ
banding/NN
techniques/NNS
,/,
these/DT
data/NNS
show/VBP
that/IN
additional/JJ
screening/NN
by/IN
either/CC
RT-PCR/NN
or/CC
FISH/NN
should/MD
be/VB
performed/VBN
in/IN
all/DT
AML/NN
M4/NN
,/,
regardless/RB
of/IN
morphologic/JJ
features/NNS
,/,
to/TO
allow/VB
accurate/JJ
evaluation/NN
of/IN
the/DT
prognostic/JJ
importance/NN
of/IN
this/DT
fusion/NN
transcript/NN
./.